Nektar Therapeutics (NKTR) Non-Current Assets (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Non-Current Assets of $174.2 million for Q1 2026, up 561.77% year-over-year from $26.3 million in Q1 2025, and up 1132.18% quarter-over-quarter from $14.1 million in Q4 2025.
Nektar Therapeutics (NKTR) Non-Current Assets (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $174.2 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 561.77% year-over-year to $174.2 million; the TTM figure through Mar 2026 stood at $229.3 million (up 65.56% YoY), while the FY2025 annual figure was $14.1 million, down 66.77% from the prior year.
- Non-Current Assets for Q1 2026 stood at $174.2 million, up from $14.1 million in the prior quarter.
- The five-year high for Non-Current Assets was $290.7 million in Q1 2022, with the low at $14.1 million in Q4 2025.
- The 5-year median for Non-Current Assets is $53.2 million (2023), against an average of $88.9 million.
- The sharpest annual moves came in 2023 and 2026: Non-Current Assets tumbled 76.19% in 2023, then surged 561.77% in 2026.
- Nektar Therapeutics' Non-Current Assets stood at $164.6 million in 2022, then tumbled by 59.1% to $67.3 million in 2023, then slumped by 36.79% to $42.6 million in 2024, then plunged by 66.77% to $14.1 million in 2025, then soared by 1132.18% to $174.2 million in 2026.
- Business Quant data shows NKTR's Non-Current Assets at $174.2 million in Q1 2026, $14.1 million in Q4 2025, and $20.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 174.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 174.23 Mn |
| Dec 31, 2025 | 14.14 Mn |
| Sep 30, 2025 | 19.99 Mn |
| Jun 30, 2025 | 20.97 Mn |
| Mar 31, 2025 | 26.33 Mn |
| Dec 31, 2024 | 42.56 Mn |
| Sep 30, 2024 | 21.49 Mn |
| Jun 30, 2024 | 48.15 Mn |
| Mar 31, 2024 | 76.18 Mn |
| Dec 31, 2023 | 67.33 Mn |
| Sep 30, 2023 | 43.22 Mn |
| Jun 30, 2023 | 53.22 Mn |
| Mar 31, 2023 | 70.68 Mn |
| Dec 31, 2022 | 164.63 Mn |
| Sep 30, 2022 | 181.52 Mn |
| Jun 30, 2022 | 196.45 Mn |
| Mar 31, 2022 | 290.66 Mn |
| Dec 31, 2021 | 321.61 Mn |
| Sep 30, 2021 | 291.11 Mn |
| Jun 30, 2021 | 315.20 Mn |